Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

They tested different concentrations of ketamine and its enantiomers, ranging from 0.002 to 10 microMolar, and examined how various mutations in the receptor affected ketamine’s ability to ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Jeff Winograd, who's lived with depression for more than 25 years, says ketamine treatment saved his life. Jeff Winograd couldn’t get off his couch. He’d hit rock bottom with the depression he ...

Ketamine, a powerful horse tranquilizer and anaesthetic, is an increasingly popular recreational drug of choice for teenagers, according to the latest government crime survey for England and Wales ...